Novartis to Spend up to $2B on Excellergy and Its Next-Gen Xolair Candidate

Why It Matters

The deal protects Novartis’ earnings from Xolair’s decline and reinforces its position in the growing allergy therapeutics market, signaling proactive defense against biosimilar disruption.

Key Takeaways

• Novartis to acquire Excellergy for up to $2B
• Deal aims to secure next‑gen anti‑IgE therapy
• Xolair faces imminent biosimilar competition
• Acquisition strengthens Novartis allergy portfolio
• Potential revenue boost beyond Xolair's decline

Pulse Analysis

Novartis’ flagship allergy drug Xolair, an anti‑IgE monoclonal antibody, has generated more than $5 billion in annual sales since its launch. However, the product is now approaching patent expiry, and a wave of biosimilars is slated to enter the U.S. and European markets within the next two years. The impending price erosion threatens to erode Novartis’ revenue stream and market share in the lucrative chronic‑hives and asthma segments. To offset this risk, the Swiss giant is actively seeking pipeline assets that can sustain its allergy franchise.

Excellergy Inc., a privately held biotech based in San Diego, has built a next‑generation anti‑IgE antibody that claims higher affinity and longer half‑life than Xolair. Early pre‑clinical data suggest the molecule can achieve deeper IgE suppression with less frequent dosing, a potential differentiator in a market crowded with biosimilars. By acquiring Excellergy, Novartis gains immediate access to this candidate, along with the company’s proprietary platform for antibody engineering. The deal also brings a seasoned development team experienced in navigating FDA pathways for allergy therapeutics.

The transaction, valued at up to $2 billion in upfront payments, reflects Novartis’ willingness to invest heavily to preserve its leadership in allergy care. Assuming a typical royalty structure, the acquisition could generate several hundred million dollars annually once the new antibody reaches market, offsetting the projected decline from Xolair biosimilars. For investors, the move signals proactive portfolio management and may support the company’s earnings guidance for the next fiscal year. Industry‑wide, the deal underscores a broader trend of big pharma buying innovative biotech to counter biosimilar disruption.